Antiviral effects of hepatitis B virus S gene-specific anti-gene locked nucleic acid in transgenic mice

Table 1 Serum hepatitis B surface antigen levels in transgenic mice (n = 7, mean ± SD)

Groups	Before treatment	After treatment
		Day 1	Day 3	Day 5	Day 7
Blank	2.34 ± 0.22	2.33 ± 0.23	2.32 ± 0.31	2.37 ± 0.30	2.35 ± 0.21
USQ	2.35 ± 0.36	2.34 ± 0.25	2.37 ± 0.31	2.31 ± 0.45	2.36 ± 0.38
LAM	2.33 ± 0.28	2.31 ± 0.38	2.27 ± 0.24	2.21 ± 0.23	2.15 ± 0.19
Anti-S-LNA	2.31 ± 0.27	2.03 ± 0.28	1.61 ± 0.11	1.55 ± 0.16	1.33 ± 0.26
Anti-G-LNA	2.35 ± 0.33	1.92 ± 0.40	1.59 ± 0.32 ab	1.27 ± 0.29ab	0.96 ± 0.18abc

^aIndicates significant differences between pre-treatment vs Anti-G-LNA (P < 0.05);

^bIndicates significant differences between Blank, USQ, LAM group vs Anti-G-LNA (P < 0.05);

^cIndicates significant differences between Anti-S-LNA vs Anti-G-LNA (P < 0.05). Values are mean ± SD. Blank: Blank control group, 5% glucose-liposome administered by tail vein injection; USQ: Unrelated sequence; LAM: Lamivudine; Anti-S-LNA: Anti-sense-LNA; Anti-G-LNA: Anti-gene-LNA; LNA: Locked nucleic acid.